Reported Low Uptake of HCV Testing among People Who Inject Drugs in Urban Vietnam

• Published in: BioMed research international Vol. 2020; no. 2020; pp. 1 - 7
• Main Authors: Giang, Le Minh, Hoa, Van Dinh, Phuong, Do Thi, Thinh, Vu Toan
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 2020; Hindawi; Hindawi Limited
• Subjects: Adult; Antiretroviral agents; Drugs; Education; Female; Global health; Health care; Health facilities; Health Services; Hepatitis C - diagnosis; Humans; Infections; Living arrangements; Logistic Models; Male; Marital status; Methadone; Public health; Questionnaires; Risk taking; Secondary schools; Substance Abuse, Intravenous - complications; Substance Abuse, Intravenous - virology; Urban Population; Vietnam; Vietnam
• ISSN: 2314-6133; 2314-6141
• DOI: 10.1155/2020/3701379

Background. HCV testing is an important first step for treatment and prevention, particularly for those who are highly vulnerable to HCV infection such as people who inject drugs (PWID). In settings where direct-acting antiretroviral medicines are becoming more available, limited information exists about who and where to target to increase the prevalence of HCV testing among PWID. This study is aimed at understanding the prevalence of HCV testing uptake and its determinants of medical services and risk behaviors. Methods. From February 2016 to April 2017, a sample of 509 PWID was interviewed using a structured questionnaire on their history of HCV testing, confirmation, services using in the previous year as well as HCV-related knowledge, and risk behaviors. Multiple logistic regression identified factors associated with ever being tested for HCV before enrollment in the program. Results. Approximately 33% reported ever testing for HCV. Most cited sources of testing are public hospitals and general clinics (68.9%) and outpatient clinics (18.9%). Having ever tested for HCV was positively associated with accessing health services within the prior 12 months (aOR=2.25; 95% CI 1.11-4.58), being currently enrolled in a methadone treatment program (aOR=2.35; 95% CI 1.34-4.08), and/or on ART treatment (aOR=2.30; 95% CI 1.30-4.08). Those who ever delayed in seeking healthcare services for any reason were less likely to get tested for HCV (aOR=0.54; 95% CI 0.35-0.84). Conclusion. HCV testing prevalence is low among PWID in Hanoi despite a very high prevalence of HCV infection. To improve the cascade of HCV testing, it is critical that intervention programs scale up linkages among methadone, outpatient clinics, and HCV services, take steps to reduce stigma and discrimination in both community and, especially, in health care settings, and increase awareness of HCV for PWID by integrating HCV into routine counseling at health care services.